Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US45784P1012
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000R7XX87
PODD

Insulet Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical Devices · THEMEFOLIO: $HLTH
NAME
Insulet Corp
ISIN
US45784P1012
TICKER
PODD
MIC
XNAS
REUTERS
PODD.OQ
BLOOMBERG
PODD US
Fr., 03.07.2026       Insulet

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation (“Insulet” or “the Company”) (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Invest...
Fr., 03.07.2026       Insulet

Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).WHAT IS THIS INVESTIGATION ABOUT? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Insulet Co...
Fr., 03.07.2026       Insulet

NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 26-cv-13062, is on behalf of a clas...
Fr., 03.07.2026       Insulet

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”). Insulet investors have until August 31, 2026 to file a lead plaintiff motion.I...
Do., 02.07.2026       Insulet

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the U.S. and interna...
Mi., 01.07.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management...
Do., 25.06.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. “We are pleased...
Sa., 06.06.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of I...
Do., 04.06.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. “At Insulet, we believe diabetes tech...
Mi., 03.06.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery (AID) System. The updates follow FDA 510(k) clearance in December 2025. Omnipod 5 is also...
Silent Ad
Mi., 27.05.2026       Insulet

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation wil...
Di., 26.05.2026       Insulet

Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delive...
Mi., 06.05.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and ex...
Di., 05.05.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet’s sustainability st...
Mo., 04.05.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D). FCL for T2D is a breakthrough innovation in...
Di., 28.04.2026       Insulet

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. (Pacific Time). The live webcast and replay of the presentation will be...
Do., 16.04.2026       Insulet

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mi., 15.04.2026       Insulet

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 15, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering...
Do., 09.04.2026       Insulet

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mo., 06.04.2026       Insulet

New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws.During that same February 18 earnings call, McEvoy stated that "strong clinical...
Silent Ad
Do., 02.04.2026       Insulet

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mi., 01.04.2026       Insulet

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 1, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering O...
Mi., 01.04.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management wil...
Mo., 30.03.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet’s global commercial organiz...
Mo., 30.03.2026       Insulet

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws.During that same February 18 earnings call, McEvoy stated that "strong clinical evidence...
Sa., 28.03.2026       Insulet

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or “the Company”) (NASDAQ: PODD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to...
Do., 26.03.2026       Insulet

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mi., 25.03.2026       Insulet

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, March 25, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering...
Mo., 23.03.2026       Insulet

New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws.During that same February 18 earnings call, McEvoy stated that "strong clinica...
Do., 19.03.2026       Insulet

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Do., 19.03.2026       Insulet

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON INSULET CORPORATION (PODD),...
Mi., 18.03.2026       Insulet

Insulet CEO Called Omnipod 5 "Reliable" and a "Favorite Pump" on February 18 -- Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective PodsNEW YORK, March 18, 2026 /PRNewswire/ -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told investors on the Q4 2025 earnings call that "our results in...
Mi., 18.03.2026       Insulet

The Law Offices of Frank R. Cruz continues its investigation of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON INSULET CORPORATION (PODD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLA...
Mi., 18.03.2026       Insulet

Law Offices of Howard G. Smith continues its investigation on behalf of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSULET CORPORATION (PODD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTEN...
Di., 17.03.2026       Insulet

New York, New York--(Newsfile Corp. - March 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws.During that same February 18 earnings call, McEvoy stated that "strong clinical evidence...
Fr., 13.03.2026       Insulet

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON...
Fr., 13.03.2026       Insulet

Law Offices of Howard G. Smith announces an investigation on behalf of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSULET CORPORATION (PODD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENT...
Fr., 13.03.2026       Insulet

The Law Offices of Frank R. Cruz announces an investigation of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON INSULET CORPORATION (PODD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAI...
Do., 12.03.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods an...
Mi., 11.03.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new clinical evidence related to the development of its first fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes. “Developing and bringing to market a...
Di., 10.03.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to its first fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D) at the 19th International Conference on Advanced Te...
Mi., 18.02.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant cur...
Do., 05.02.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE)....
Fr., 09.01.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, mana...
Di., 06.01.2026       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, an...
Di., 16.12.2025       Insulet

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation...
Mo., 15.12.2025       Insulet

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers. “Here at Insulet, our mission is to transform the lives of people with diabetes, and...
Do., 04.12.2025       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in...
Do., 20.11.2025       Insulet

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company’s global headquarters in Acton, Massachusetts. During the event, Insulet’s executive team outlined the strategic plan and innovation roadmap...
Do., 06.11.2025       Insulet

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency...